Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Research & Development (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Research & Development for 13 consecutive years, with $116.3 million as the latest value for Q4 2025.

  • Quarterly Research & Development rose 215.09% to $116.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $388.5 million through Dec 2025, up 56.68% year-over-year, with the annual reading at $388.5 million for FY2025, 64.13% up from the prior year.
  • Research & Development for Q4 2025 was $116.3 million at Madrigal Pharmaceuticals, down from $174.0 million in the prior quarter.
  • The five-year high for Research & Development was $174.0 million in Q3 2025, with the low at $36.9 million in Q4 2024.
  • Average Research & Development over 5 years is $68.0 million, with a median of $65.2 million recorded in 2022.
  • The sharpest move saw Research & Development plummeted 47.76% in 2024, then surged 215.09% in 2025.
  • Over 5 years, Research & Development stood at $52.9 million in 2021, then surged by 33.76% to $70.7 million in 2022, then fell by 0.14% to $70.6 million in 2023, then plummeted by 47.76% to $36.9 million in 2024, then soared by 215.09% to $116.3 million in 2025.
  • According to Business Quant data, Research & Development over the past three periods came in at $116.3 million, $174.0 million, and $54.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.